Bifogade filer
PDF
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Uppsala, July 1, 2025. OssDsign AB (publ.) announces that the exercise period for the long-term incentive warrant program 2022/2025 starts today on July 1.
Approximately 1.5 million warrants have been issued to board members, executives and employees as part of the long-term incentive program adopted at OssDsign's Annual General Meeting in 2022. According to the program, warrants can be exercised to buy shares (1 share per warrant) between July and December 2025. If all warrants are converted to shares, the company will receive approximately SEK 10 million.
In conjunction with the directed share issue that was announced on June 3, 2025, OssDsign's board members and members of senior management have undertaken not to divest any shares in OssDsign for a period of 180 days from the settlement date. Shares obtained through OssDsigns 2022/2025 incentive programs are exempted from these lock-up restrictions.
For further information, please contact:
Morten Henneveld, CEO, OssDsign AB
Tel: +46 73 382 43 90, email: morten.henneveld@ossdsign.com
Certified Adviser:
The Company's Certified Adviser is DNB Carnegie Investment Bank AB.
About OssDsign®
OssDsign is a developer and global provider of next generation orthobiologics products. Based on cutting edge material science, the company develops and markets products that support the body's own healing capabilities, giving patients back the life they deserve. The company has a strong presence in the U.S. market. OssDsign's share is traded on Nasdaq First North Growth Market in Stockholm, Sweden.